Innate immunity as a target for novel therapeutics in triple negative breast cancer

References

• Jessy T. Immunity over inability: the spontaneous regression of cancer. J Nat Sci Biol Med. 2011 Jan-Jun; 21(1): 43–49.
   Google Scholar
• Dobosz P, Dzieciatkowski T. The Intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5 377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase IB KEYNOTE-012 study. J Clin Oncol. 2016 Jul 20;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019 Mar 1;30(3):397–404.
   PubMed Web of Science ®Google Scholar
• Xiao BY, Lin GH, Zhao YX, et al. The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. Transl Cancer Res. 2020 Jun;9(6):3804–3818.
   PubMedGoogle Scholar
• Miles D, Gligorov J, André F, et al. IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994–1004.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, Im SA, et al. KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499–511.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31(3):387–394.
   PubMed Web of Science ®Google Scholar
• Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018 Jan;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837–1846.
   PubMed Web of Science ®Google Scholar
• Emens LA, Molinero L, Adams S, et al. 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: exploratory analysis of the phase III IMpassion130 trial. Ann Oncol. 2020;31:S360–S361.
   Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559–569.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab -paclitaxel–treated advanced triple-negative breast cancer. J. Natl Cancer Inst. 2021; 113: 1733–1743.
   PubMedGoogle Scholar
• Brown TA 2nd, Mittendorf EA, and Hale DF, et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181:391–401. DOI:https://doi.org/10.1007/s10549-020-05638-x
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–2467.
   PubMed Web of Science ®Google Scholar
• Nanda R, Specht J, Dees C, et al. KEYNOTE-012: long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Presented at: 2016 San Antonio Breast Cancer Symposium, San Antonio, Texas, 6–10 December 2016. Abstract P6–10–03.
   Google Scholar
• Clinical Trial. A phase I, open-label, dose-escalation study of the safety and pharmacokinetics of atezolizumab (MPDL3280A) administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors https://www.clinicaltrials.gov/ct2/show/NCT02298153.
   Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Cohort A, cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–411.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–686.
   PubMed Web of Science ®Google Scholar
• Cortes J, Lipatov O, S-A I, et al. Keynote-119: pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol. 2019;30:v859–v860.
   PubMed Web of Science ®Google Scholar
• Falvo P, Orecchioni S, Hillje R, et al. Cyclophosphamide and vinorelbine activate stem-like CD8(+) T cells and improve anti-PD-1 efficacy in triple-negative breast cancer. Cancer Res . 2021;81(3):685–697.
   PubMedGoogle Scholar
• Schmid P, Adams S, Rugo HS, et al. IMpassion130 trial investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29; 379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Kok M, Horlings HM, van de Vijver K, et al. Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Ann Oncol. 2017;28:v608.
   Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med . 2019;25(6):920–928.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon D, Rugo H, et al. Chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–1828.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Schmid P, Cescon DW, et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Presented at: SABCS 2020. Virtual, 10 December 2020. Abstract #GS3-01
   Google Scholar
• Rugo HS, Cortes J, and Cescon DW, et al. KEYNOTE-355: final results from a randomized, double-blind phase 3 study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Presented at: ESMO Congress 2021. Abstract #LBA16 17 to 21 September 2021 Paris, France.
   Google Scholar
• Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32:1198–1200.
   Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022 Feb 10;386(6):556–567.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb 27 382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–1100.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP michelangelo randomized study. Ann Oncol. Published online 16 February 2022;33:534–543.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, and Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine. 2004;10(9):909–915.
   PubMed Web of Science ®Google Scholar
• Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Update. 2017 May;32:1–15.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Wang ML, Yee AJ, et al. Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial. JAMA Oncol. 2018;4:e183267.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Tolaney SM, Tung NM. A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer. J Clin Oncol. 2017;35:2–3. DOI:https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS1126.
   Google Scholar
• Lacher MD, Bauer G, Fury B, et al. SV-BR-1-GM, a clinically effective GM-CSF-secreting breast cancer cell line, expresses an immune signature and directly activates CD4+ T lymphocytes. Front Immunol. 2018 May 15;9:776. DOI:https://doi.org/10.3389/fimmu.2018.00776.
   PubMedGoogle Scholar
• Papadimitriou M, Liakouli Z, Papadimitriou CA. The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives. J Cancer Metastasis Treat. 2021;7:63.
   Google Scholar
• Thomas R, Al-Khadairi G, Roelands J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018 May 1; 9:947.
   PubMed Web of Science ®Google Scholar
• Brown TA 2nd, Mittendorf EA, Hale DF, et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2): 391–401.
   PubMed Web of Science ®Google Scholar
• Humeau J, Le Naour J, Galluzzi L, et al. Trial watch: intratumoral immunotherapy. Oncoimmunology. 2021 Oct 15;10(1):1984677.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018 Apr 17;48(4):812–830.e14.
   PubMed Web of Science ®Google Scholar
• Gruosso T, Gigoux M, Manem VSK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019 Apr 1;129(4):1785–1800.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368.
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 1;21(7):1688–1698.
   PubMed Web of Science ®Google Scholar
• Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb 4;4(2):232–245.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Steeg PS, Stetler-Stevension WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327.
   PubMed Web of Science ®Google Scholar
• Wernert N. The multiple roles of tumor stroma. Virchows Arch. 1997;430:433–443.
   PubMed Web of Science ®Google Scholar
• Xing F. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 2010 Jan 1;15(1):166–179. (Landmark Ed).
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• de Mingo Pulido Á, Ruffell B, Hiebler S, et al. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018;33(1):60–74.
   PubMed Web of Science ®Google Scholar
• Bai X, Jie N, Beretov J, et al. Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance. J National Cancer Center. 2021;1(3):75–87.
   Google Scholar
• Gatti-Mays ME, Balko JM, Gameiro SR, et al. If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer. 2019;5:37.
   PubMed Web of Science ®Google Scholar
• Carlino F, Diana A, Piccolo A, et al. Immune-based therapy in triple-negative breast cancer: from molecular biology to clinical practice. Cancers (Basel). 2022;14:2102.
   PubMedGoogle Scholar
• Zhang Y, Chen H, Mo H, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021 Dec 13;39(12):1578–1593.
   PubMedGoogle Scholar
• Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021 Jun 14;39(6):845–865.
   PubMed Web of Science ®Google Scholar
• Bassez A, Vos H, Van Dyck L, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021 May;27(5):820–832.
   PubMed Web of Science ®Google Scholar
• Deng J, Thennavan A, Shah S, et al. Serial single-cell profiling analysis of metastatic TNBC during nab-paclitaxel and pembrolizumab treatment. Breast Cancer Res Treat. 2021 Jan;185(1):85–94.
   PubMedGoogle Scholar
• Medzhitov R, Janeway CA Jr. Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol. 1999;64:429–435.
   PubMedGoogle Scholar
• Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017 Jan;24(1):3–15.
   PubMed Web of Science ®Google Scholar
• Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30–50.
   PubMed Web of Science ®Google Scholar
• CA J Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(1):1–13.
   Google Scholar
• Medzhitov R. Pattern recognition theory and the launch of modern innate immunity. J Immunol. 2013 Nov 1;191(9):4473–4474.
   PubMed Web of Science ®Google Scholar
• Takahama S, Yamamoto T. Pattern receptor ligands as an emerging therapeutic agent for latent HIV-1 infection. Front Cell Infect Microbiol. 2020;10:216.
   PubMedGoogle Scholar
• Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20;41(5):830–842.
   PubMed Web of Science ®Google Scholar
• Corrales L, McWhirter SM, TW D Jr, et al. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 Jul 1;126(7):2404–2411.
   PubMed Web of Science ®Google Scholar
• Klarquist J, Hennies C, Lehn M, et al. STING -mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol. 2014;193(12):6124–6134.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003.
   PubMed Web of Science ®Google Scholar
• Ramanjulu J, Pesiridis G, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564(20/27):439–443.
   PubMedGoogle Scholar
• Vyskocil S, Cardin D, Ciavarri J, et al. Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route. J Med Chem. 2021;64:6902–6923.
   PubMedGoogle Scholar
• He L, Xiao X, Yang X, et al. STING signaling in tumorigenesis and cancer therapy: a friend or foe? Cancer Lett. 2017 Aug 28;402:203–212.DOI:https://doi.org/10.1016/j.canlet.2017.05.026
   PubMed Web of Science ®Google Scholar
• Chandra D, Quispe-Tintaya W, Jahangir A, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014 Sep;2(9):901–910.
   PubMed Web of Science ®Google Scholar
• Milling LE, Garafola D, and Agarwal Y, et al. Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation. Cancer Immunol Res. 2022 Jan;10(1):26–39.
   PubMedGoogle Scholar
• Meric-Bernstam F, Sweis RF, Hodi FS, et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin Cancer Res. 2022 Feb 15;22(4):677–688.
   Google Scholar
• Bukhalid RA, Duvall JR, Cetinbas NM, et al. Abstract 6706: systemic administration of IV STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines. Cancer Res. 2020;80(16_Supplement):6706.
   Web of Science ®Google Scholar
• Kirwin K, Jang SC, Sia C, et al. Abstract 572:combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity. JITC. 2021;9(Suppl 2).
   Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376.
   PubMed Web of Science ®Google Scholar
• Rameshbabu S, Labadie BW, Argulian A, et al. Targeting innate immunity in cancer therapy. Vaccines (Basel). 2021 Feb 9;9(2):138.
   PubMedGoogle Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001 Aug;2(8):675–680.
   PubMed Web of Science ®Google Scholar
• Li JK, Balic JJ, Yu L, et al. TLR agonists as adjuvants for cancer vaccines. Adv Exp Med Biol. 2017;1024:195–212.
   PubMed Web of Science ®Google Scholar
• Guney Eskiler G, Özkan A D. The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer. Mol Immunol. 2022 Jan;141:280–286.
   PubMed Web of Science ®Google Scholar
• Francian A, Widmer A, Olsson T, et al. Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth. J Drug Target. 2021 Aug;29(7):754–760.
   PubMedGoogle Scholar
• Shayan G, Kansy BA, Gibson SP, et al. Phase Ib study of Immune biomarker modulation with neoadjuvant cetuximab and tlr8 stimulation in head and neck cancer to overcome suppressive myeloid signals. Clin Cancer Res. 2018 Jan 1;24(1):62–72.
   PubMed Web of Science ®Google Scholar
• Siu L, Brody J, Gupta S, et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 Oct;8(2):e001095.
   PubMedGoogle Scholar
• Babiker HB, Lenz H-J, Scott AJ, et al. Abstract CT265: a phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206). Cancer Res 15 August 2020;80 (16_Supplement): CT265.
   Google Scholar
• Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Aug;11(8):1996–2013.
   PubMed Web of Science ®Google Scholar
• Chein AJ, Soliman HS, Ewing CA, et al. I-SPY 2 TRIAL consortium. Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: results from the I-SPY 2 trial. J Clin Oncol. 2021;39(15):abstr 508.
   Google Scholar
• Diab A, Marcondes M, Kotzin B, et al. Phase Ib: preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL phase Ib/II trial). J Clin Oncol. 2019;37(8):26.
   Google Scholar
• Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6748–6757.
   PubMed Web of Science ®Google Scholar
• Rozenblit M, Hendrickx W, Heguy A, et al. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with imiquimod. Sci Rep. 2019 Jun 12 9(1):8572.
   PubMedGoogle Scholar
• Salazar LG, Lu H, Reichow JL, et al. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017 Jul 1;3(7):969–973.
   PubMedGoogle Scholar
• Singh B, Maharjan S, Pan DC, et al. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials. 2022 Jan;280:121302.
   PubMedGoogle Scholar
• Yasothamani V, Karthikeyan L, Shyamsivappan S, et al. Synergistic effect of photothermally targeted nir-responsive nanomedicine-induced immunogenic cell death for effective triple negative breast cancer therapy. Biomacromolecules. 2021 Jun 14;22(6):2472–2490.
   PubMedGoogle Scholar
• Yan J, Zhang Z, Zhan X, et al. In situ injection of dual-delivery PEG based MMP-2 sensitive hydrogels for enhanced tumor penetration and chemo-immune combination therapy. Nanoscale. 2021 Jun 3;13(21):9577–9589.
   PubMedGoogle Scholar
• Wei X, Liu L, Li X, et al. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. J Control Release. 2019 Nov 10;313:42–53. DOI:https://doi.org/10.1016/j.jconrel.2019.09.021.
   PubMedGoogle Scholar
• Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates. Science. 2006 Nov 10;314(5801):997–1001.
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yamada T. Regulation of signaling mediated by nucleic acid sensors for innate interferon-mediated responses during viral infection. Int Immunol. 2019 Jul 30;31(8):477–488.
   PubMedGoogle Scholar
• Jiang X, Kinch LN, Brautigam CA, et al. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity. 2012 Jun 29; 36(6):959–973.
   PubMed Web of Science ®Google Scholar
• Rameshbabu S, Labadie BW, Argulian A, et al. Targeting innate immunity in cancer therapy. Vaccines (Basel). 2021 Feb 9;9(2):138.
   PubMedGoogle Scholar
• Elion DL, Jacobson ME, Hicks DJ, et al. Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res. 2018 Nov 1;78(21):6183–6195.
   PubMed Web of Science ®Google Scholar
• Zheng W, Ranoa DRE, Huang X, et al. RIG-I-like receptor LGP2 is required for tumor control by radiotherapy. Cancer Res. 2020 Dec 15;80(24):5633–5641.
   PubMed Web of Science ®Google Scholar
• Iurescia S, Fioretti D, Rinaldi M. The innate immune signalling pathways: turning RIG-I sensor activation against cancer. Cancers (Basel). 2020 Oct 27;12(11):3158.
   Google Scholar
• Kyi C, Roudko V, Sabado R, et al. Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. Clin Cancer Res. 2018 Oct 15 24(20):4937–4948.
   PubMed Web of Science ®Google Scholar
• Rameshbabu S, Labadie BW, Argulian A, et al. Targeting innate immunity in cancer therapy. Vaccines (Basel). 2021;9(2):138.
   PubMedGoogle Scholar
• Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020 Feb 27;9(3):561.
   PubMed Web of Science ®Google Scholar
• Zhang X, Fu X, Li T, et al. The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2019 Dec 2;14(12):e0225327.
   PubMed Web of Science ®Google Scholar
• Ai L, Mu S, Wang Y, et al. Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer. 2018 Dec 5;18(1):1220.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma X, Zhu C, et al. The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLoS One. 2016 Oct 25;11(10):e0164514.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009 Jan;58(1):49–59.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Padget MR, Fujii R, et al. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J Immunother Cancer. 2021 Feb;9(2):e001691.
   PubMed Web of Science ®Google Scholar
• Parveen S, Siddharth S, Cheung LS, et al. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model. Mol Oncol. 2021 May;15(5):1330–1344.
   PubMedGoogle Scholar
• Pestel R, Cristofanilli M, Rui H, et al. Abstract PD4-04: leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies. Cancer Res February 15 2020;80(4 Supplement) PD4–04.
   Google Scholar
• Chandrasekaran S, Funk CR, Kleber T, et al. Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-δ and -γ. Front Immunol. 2021;12:718621.
   PubMedGoogle Scholar
• Sullivan RJ, Hong DS, Tolcher AW, et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. J clin oncol. May 20, 2018;36(15_suppl):3013.
   Google Scholar
• Yang J, Yan C, Vilgelm AE, et al. Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity. Cancer Immunol Res. 2021 Feb;9(2):200–213.
   PubMedGoogle Scholar
• Zhu H, Gu Y, Xue Y, et al. CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. Oncotarget. 2017 Dec 7;8(70):114554–114567.
   PubMedGoogle Scholar
• Goldstein LJ, Mansutti M, Levy C, et al. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Res Treat. 2021 Nov;190(2):265–275.
   PubMed Web of Science ®Google Scholar
• Mehta AK, Kadel S, Townsend MG, et al. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021 Apr 23;12:643771. DOI:https://doi.org/10.3389/fimmu.2021.643771
   PubMed Web of Science ®Google Scholar
• Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014 May 23;344(6186):921–925.
   PubMed Web of Science ®Google Scholar
• Chung W, Eum HH, Lee HO, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017 May 5;8:15081. DOI:https://doi.org/10.1038/ncomms15081.
   PubMed Web of Science ®Google Scholar
• Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014 Feb 20;40(2):274–288.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011 Mar 25;331(6024):1565–1570.
   PubMed Web of Science ®Google Scholar
• Strack E, Rolfe PA, Fink AF, et al. Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis. Clin Transl Med. 2020 Dec;10(8):e239.
   PubMedGoogle Scholar
• Arole V, Nitta H, Wei L, et al. M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma. Breast Cancer Res Treat. 2021 Jul;188(1):37–42.
   PubMedGoogle Scholar
• Autio KA, Klebanoff CA, Schaer D, et al. Immunomodulatory Activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase i study. Clin Cancer Res. 2020 Nov 1;26(21):5609–5620.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Harvey RD, Carvajal RD, et al. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Invest New Drugs. 2021 Aug;39(4):1057–1071.
   PubMedGoogle Scholar
• Falchook GS, Peeters M, Rottey S, et al. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Invest New Drugs. 2021 Oct;39(5):1284–1297.
   PubMedGoogle Scholar
• Strachan DC, Ruffell B, Oei Y, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013 Dec 1;2(12):e26968.
   PubMed Web of Science ®Google Scholar
• Lin C-C, Gil-Martin M, Bauer TM, et al. Abstract CT171: phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors. Cancer Res. 15 August 2020;80(16_Supplement):CT171.
   Google Scholar
• Lin -C-C. Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors. J Immunother Precis Oncol. 1 May 2021;4(2):105–114.
   PubMedGoogle Scholar
• Luke JJ, Saba Azad N, Edwards R, et al. Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine. J clin oncol. 2018;36(15): TPS3101–TPS3101.
   Google Scholar
• Kuemmel S, Campone M, Loirat D, et al. A randomized phase ii study of anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple-negative breast cancer. Clin Cancer Res. 2022 Jan 1;28(1):106–115.
   PubMedGoogle Scholar
• Mehta AK, Cheney EM, Hartl CA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 Jan;2(1):66–82.
   PubMedGoogle Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007 May;121(1):1–14.
   PubMed Web of Science ®Google Scholar
• Shaver KA, Croom-Perez TJ, Copik AJ. Natural killer cells: the linchpin for successful cancer immunotherapy. Front Immunol. 2021 Apr 28;12:679117.DOI:https://doi.org/10.3389/fimmu.2021.679117
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018 May 4;9:847.DOI:https://doi.org/10.3389/fimmu.2018.00847
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018 Feb 22;172(5):1022–1037.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 Aug;24(8):1178–1191.
   PubMed Web of Science ®Google Scholar
• Pesce S, Trabanelli S, Di Vito C, et al. Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes. Cancers (Basel). 2020;12:3504.
   PubMedGoogle Scholar
• Haanen JB, Cerundolo V. NKG2A, a New kid on the immune checkpoint block. Cell. 2018 Dec 13;175(7):1720–1722.
   PubMed Web of Science ®Google Scholar
• van Montfoort N, Borst L, Korrer MJ, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018 Dec 13 175(7):1744–1755.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018 Dec 13;175(7):1731–1743.e13.
   PubMed Web of Science ®Google Scholar
• Galot R, Le Tourneau C, Saada-Bouzid E, et al. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur J Cancer. 2021 Oct 9;158:17–26.
   PubMed Web of Science ®Google Scholar
• Tinker AV, Hirte HW, Provencher D, et al. Dose-ranging and cohort-expansion study of monalizumab (IPH2201) in patients with advanced gynecologic malignancies: a trial of the Canadian Cancer Trials Group (CCTG): IND221. Clin Cancer Res. 2019 Oct 15;25(20):6052–6060.
   PubMedGoogle Scholar
• van Hall T, André P, Horowitz A, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Pende D, et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med. 1990 Dec 1 172(6):1589–1598.
   PubMedGoogle Scholar
• Vey N, Karlin L, Sadot-Lebouvier S, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 2018 Apr 3;9(25):17675–17688.
   PubMedGoogle Scholar
• Grivas P, Yin J, Koshkin VS, et al. PrE0807: a phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol 2021;39(15):4518.
   Google Scholar
• Chen G, Shi L, Litchfield DW, et al. Rescue from granzyme B induced apoptosis by Wee1 kinase. J Exp Med. 1995;181:2295–2300.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Pavlick AC, et al. Phase I study evaluating WEE1 Inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016 Dec 20;34(36):4371–4380.
   PubMed Web of Science ®Google Scholar
• Friedman J, Morisada M, Sun L, et al. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. J Immunother Cancer. 2018 Jun 21;6(1):59.
   PubMedGoogle Scholar
• Keenan TE, Li T, Vallius T, et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin Cancer Res. 2021 Feb 15;27(4):983–991.
   PubMed Web of Science ®Google Scholar
• Tutt A, Stephens C, and Frewer P, et al. VIOLETTE: a randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes Journal of clinical oncology . 2018 35 15 doi:https://doi.org/https://doi.org/10.1200/JCO.2018.36.15-suppl.TPS1116 ; TPS1116–TPS1116.
   Google Scholar
• Hong DS, Schoffski P, Calvo A, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. J clin oncol. 2018;36(15):3012.
   Google Scholar
• Mittendorf E, Barrios CH, Harbeck N, et al. Abstract OT2-07-03: iMpassion031: a phase III study comparing neoadjuvant atezolizumab vs placebo in combination with nab-paclitaxel–based chemotherapy in early triple-negative breast cancer (TNBC). Cancer Res. 15 February 2018;78(4_Supplement):OT2–07–03.
   Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812–830.e14.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
   PubMed Web of Science ®Google Scholar
• Kulasinghe A, Monkman J, and Shah ET, et al. Spatial profiling identifies prognostic features of response to adjuvant therapy in triple negative breast cancer (TNBC). Front Oncol. 2022 Jan 10;11:798296. DOI:https://doi.org/10.3389/fonc.2021.798296.
   PubMedGoogle Scholar